Multivariate analysis of factors associated with PFS after ASCT for myeloma
| Patient group . | No. . | RR (95%CI) . | P . |
|---|---|---|---|
| GR KIR3DS1− | 100 | 1.0 | |
| GR KIR3DS1+ | 46 | 1.9 (1.3-3.1) | .002 |
| Bad risk KIR3DS1+ or KIR3DS1− | 33 | 3.0 (1.9-4.8) | < .001 |
| Adjusted for albumin, β2M | |||
| GR KIR3DS1− | 89 | 1.0 | |
| GR KIR3DS1+ | 41 | 1.8 (1.2-2.8) | .008 |
| Bad risk KIR3DS1+ or KIR3DS1− | 33 | 2.7 (1.6-4.3) | .001 |
| Adjusted for albumin, β2M, and cytogenetics | |||
| GR KIR3DS1− | 36 | 1.0 | |
| GR KIR3DS1− | 12 | 2.7 (1.2-6.2) | .021 |
| Bad risk KIR3DS1+ or KIR3DS− | 20 | 5.3 (2.4-11.7) | < .001 |
| Patient group . | No. . | RR (95%CI) . | P . |
|---|---|---|---|
| GR KIR3DS1− | 100 | 1.0 | |
| GR KIR3DS1+ | 46 | 1.9 (1.3-3.1) | .002 |
| Bad risk KIR3DS1+ or KIR3DS1− | 33 | 3.0 (1.9-4.8) | < .001 |
| Adjusted for albumin, β2M | |||
| GR KIR3DS1− | 89 | 1.0 | |
| GR KIR3DS1+ | 41 | 1.8 (1.2-2.8) | .008 |
| Bad risk KIR3DS1+ or KIR3DS1− | 33 | 2.7 (1.6-4.3) | .001 |
| Adjusted for albumin, β2M, and cytogenetics | |||
| GR KIR3DS1− | 36 | 1.0 | |
| GR KIR3DS1− | 12 | 2.7 (1.2-6.2) | .021 |
| Bad risk KIR3DS1+ or KIR3DS− | 20 | 5.3 (2.4-11.7) | < .001 |
Patients were stratified into 3 groups based on (1) disease status at ASCT; (2) KIR3DS1 genotype; and (3) good risk KIR3DS1−, good risk KIR3DS1+, poor-risk patients. The RR after further adjustment for albumin level, β2M level, and bone marrow cytogenetics are also shown.
RR indicates relative risk; 95% CI, 95% confidence interval; GR, good risk; and β2M, β-2 microglobulin.